SCHEMBL21045121

SCHEMBL21045121

Cc1ncccc1C(=O)NCCCc1ccc(-c2cc(C)c3[nH]ncc3c2)cc1

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 3/20 0.43
HPGD P15428 2/20 0.43
PTAFR P25105 2/20 0.42
NPC1 O15118 1/20 0.42
RAB9A P51151 1/20 0.42
KDM4B O94953 1/20 0.40
CNR1 P21554 1/20 0.40
ROCK2 O75116 1/20 0.40
ROCK1 Q13464 1/20 0.40
P2RX7 Q99572 1/20 0.39
GSK3B P49841 1/20 0.39
MEN1 O00255 2/20 0.39
KMT2A Q03164 2/20 0.39
EGLN1 Q9GZT9 1/20 0.39
EPHX2 P34913 1/20 0.39
SMYD2 Q9NRG4 1/20 0.38
KDM4E B2RXH2 1/20 0.38
ALDH1A1 P00352 1/20 0.38
RXFP1 Q9HBX9 1/20 0.38
TP53 P04637 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL21045196 0.87 ROCK2 (0.49) SMN1; SMN2HPGDPTAFRNPC1RAB9A
SCHEMBL29411659 0.87 ROCK2 (0.49) SMN1; SMN2HPGDPTAFRNPC1RAB9A
SCHEMBL21045284 0.84 KDM4E (0.50) PTAFRGSK3BEPHX2KDM4EALDH1A1
SCHEMBL21045204 0.81 RXRA (0.40) SMN1; SMN2PTAFRNPC1RAB9ACNR1
SCHEMBL21045126 0.80 FLT3 (0.54)
SCHEMBL21118917 0.79 HPGD (0.41) SMN1; SMN2HPGDPTAFRNPC1CNR1
SCHEMBL21045402 0.79 KDM4B (0.46) SMN1; SMN2HPGDPTAFRNPC1RAB9A
SCHEMBL29411607 0.79 KDM4B (0.46) SMN1; SMN2HPGDPTAFRNPC1RAB9A
SCHEMBL21045085 0.78 HDAC3 (0.38) SMN1; SMN2PTAFRNPC1RAB9ACNR1
SCHEMBL21100619 0.78 SMN1; SMN2 (0.48) SMN1; SMN2HPGDPTAFRNPC1RAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250188035-A1 TUBULIN INHIBITORS LIN BIOSCIENCE LLC (US) 2025-06-12 US disclosed
US-12247010-B2 Tubulin inhibitors LIN BIOSCIENCE INC. (TW) 2025-03-11 US disclosed
US-20220089539-A1 TUBULIN INHIBITORS LIN BIOSCIENCE INC. (TW) 2022-03-24 US disclosed
US-20220089539-A1 TUBULIN INHIBITORS LIN BIOSCIENCE INC. (TW) 2022-03-24 US disclosed
US-11040945-B2 Tubulin inhibitors LIN BIOSCIENCE PTY LTD. 2021-06-22 US disclosed
US-11040945-B2 Tubulin inhibitors LIN BIOSCIENCE PTY LTD. 2021-06-22 US disclosed
WO-2019113242-A1 TUBULIN INHIBITORS Lin BioScience, LLC (US) 2019-06-13 WO disclosed
US-20190169127-A1 TUBULIN INHIBITORS LIN BIOSCIENCE INC. (TW) 2019-06-06 US disclosed
US-20190169127-A1 TUBULIN INHIBITORS LIN BIOSCIENCE INC. (TW) 2019-06-06 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220089539-A1 TUBULIN INHIBITORS TUBB3, TUBB1, TUBB SMN1; SMN2 1062/4885HPGD 3869/4885PTAFR 2124/4885
US-12247010-B2 Tubulin inhibitors TUBB3, TUBB1, TUBB SMN1; SMN2 1062/4885HPGD 3869/4885PTAFR 2124/4885
US-11040945-B2 Tubulin inhibitors TUBB3, TUBB1, TUBB SMN1; SMN2 1062/4885HPGD 3869/4885PTAFR 2124/4885
US-20250188035-A1 TUBULIN INHIBITORS TUBB3, TUBB1, TUBB SMN1; SMN2 1062/4885HPGD 3869/4885PTAFR 2124/4885
US-20190169127-A1 TUBULIN INHIBITORS TUBB3, TUBB1, TUBB SMN1; SMN2 1062/4885HPGD 3869/4885PTAFR 2124/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.